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ABSTRACT 
This work aims to develop poly(d,l-lactide-co-glycolide) (PLGA)-nanospheres containing 
amphotericin B (AmB) with suitable physicochemical properties and anti-parasitic activity for 
visceral leishmaniasis (VL) therapy. When compared with unloaded-PLGA-nanospheres, the 
AmB-loaded PLGA-nanospheres displayed an increased particle size without affecting the 
polydispersity and its negative surface charge. AmB stability in the PLGA-nanospheres was 
> 90% over 60-days at 30 °C. The AmB-PLGA-nanospheres demonstrated significant in 
vitro and in vivo efficacy and preferential accumulation in the visceral organs. In addition, an 
immune-modulatory effect was observed in mice treated with AmB-PLGA-nanospheres, 
correlating with improved treatment efficacy. The in vitro cytotoxic response of the T-
lymphocytes revealed that AmB-PLGA-nanospheres efficacy against VL infection was 
strictly due to the action of CD8
+
- but not CD4
+
-T lymphocytes. Overall, we demonstrate a 
crucial role for CD8
+
 cytotoxic T lymphocytes in the efficacy of AmB-PLGA nanospheres, 
which could represent a potent and affordable alternative for VL therapy. 
FROM THE CLINICAL EDITOR 
This study demonstrates a crucial role for CD8+ T lymphocytes in eliminating visceral 
leishmaniasis in a murine model by enhancing the cytotoxic efficacy of CD8+ T-cells via 
amphotericin-B-PLGA nanospheres, paving a way to a unique, potentially more potent and 
cost-effective therapeutic strategy. 
INTRODUCTION 
Amphotericin B (AmB) is a polyene antibiotic, approved by the FDA, which is commonly 
used to treat invasive fungal infections and as second-line drug in the treatment of visceral 
leishmaniasis (VL). AmB is a produced by Streptomyces sp. and has low solubility at 
physiological pH (< 0.1 mg/mL), which restrains the development of pharmaceutical 
formulations for oral and parenteral administrations (1, 2). The connection between its 
physico-chemical properties, pharmacokinetics and pharmacodynamics remains uncertain 
(3-5). It has a high VL curative rate but requires prolonged period of treatment and 
hospitalization, leading to renal toxicity, among other severe adverse reactions. Indeed, the 
extensive association of AmB with low density lipoproteins (LDL) and the internalization of 
the AmB-LDL complex by kidney cells rich in high affinity LDL receptors responsible for the 
nephrotoxicity is well known (4, 6).  
Leishmaniasis is a protozoan disease spread in nearly one hundred countries worldwide and 
is listed as the second major human neglected tropical disease in terms of mortality and 
morbidity with 350 million people living at risk, and a prevalence of 2 million cases a year, of 
which 0.5 million cases are of VL, a potentially fatal disease if left untreated. However, the 
treatment options are limited and unsatisfactory since most available drugs require parenteral 
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administration and present serious toxicity with the occurrence of resistant strains contributing 
to hamper their success. 
Drug delivery systems (DDSs) are a well-established approach to improve the therapeutic 
efficiency of drugs with concomitant reduction of drug toxicity. Several AmB lipid formulations 
(AmBisome®, Amphocil® and Abelcet®) and other DDSs have been developed in the past 
few years, but only the liposomal formulation AmBisome® has become a standard treatment 
for VL (6, 7).  Recently, a single-course therapy of 10 mg/kg has been shown to cure 95% of 
VL patients in India (8). AmBisome® is significantly less toxic than the conventional AmB 
colloidal dispersion with sodium deoxycholate (Fungizone®) developed in 1958 (9, 10) since 
the former alters the pharmacokinetics, distribution and excretion profiles of AmB by 
decreasing free AmB concentrations in plasma as a result of encapsulation of the drug in 
liposomes(11, 12). Still, there are limitations for AmBisome® treatment among which the high 
cost and temperature stability (recommended 25 °C for unopened vials of lyophilized material 
and 2-8 °C/24 h for reconstituted vials, accordingly to the manufacturer) comprise the major 
drawbacks.
5
 Moreover, AmB repeated administrations result in its accumulation due to slow 
elimination from the body, ultimately leading to nephrotoxicity (13). In view of all these facts, 
the search for a safer, more potent and especially more cost-effective AmB delivery system 
still remains. Recently, new DDSs for AmB have been described but some issues related with 
efficacy, toxicity and stability sill remain (14-19).  
The present work aims to produce a nanospheres-based delivery system for AmB in an 
attempt to develop a cost-effective formulation with reduced toxicity, increased temperature 
stability and retaining its efficiency to VL treatment. To overcome AmB’s drawbacks, we 
considered that a low-dose therapeutic system for AmB is desirable, aiming specifically to 
reduce the side-effects while maintaining its anti-parasitic efficacy. In order to develop such a 
delivery system for AmB, polymeric nanospheres (NS) based on Poly(D,L-lactide-co-glycolide) 
(PLGA) were selected due to their sustained-release characteristics, easy scale up, simple 
transformation, small particle size, biodegradability and biocompatibility properties (20). These 
are crucial properties to ensure an intracellular delivery and sustained release of drugs at a 
therapeutically relevant level (21). Here, we report the preparation and physicochemical 
characterization of the AmB-PLGA-NS followed by the in vitro and in vivo evaluation of the 
anti-leishmanial activity in comparison to free AmB or its commercially available lipid 
formulations. In parallel, we evaluated the in vivo AmB’s distribution and drug-induced toxicity 
in several organs and unravel the probable interaction of this novel nano-formulation with the 
immune response. 
METHODS 
Detailed descriptions of the materials and methods can be found in the Supplementary 
Material 
Ethics statement. All procedures involving animals were approved by and performed in 
accordance with the Portuguese National Authority for Animal Health license (0042/000/2012) 
and, the requirements and regulations laid down by the ethical review of IBMC-INEB Animal 
Ethics Committee. 
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Preparation and physical characterization of AmB-loaded PLGA nanospheres. Drug 
loaded PLGA-NS were prepared based on the nanoprecipitation method (22). The mean 
particle size, size distribution and zeta potential (ζ-potential) of the nanoformulations were 
determined with a Zetasizer Nano ZS detector (Malvern Instruments, Worcestershire, UK). 
The morphology of NS was observed by transmission electronic microscopy (TEM) (TEM Jeol 
JEM-1400, Tokyo, Japan). AmB loading on the PLGA-NS was determined directly by 
measuring the amount of drug entrapped in the NS by an Ultra Performance Liquid 
Chromatography (UPLC) method described in the Supplementary Material (Table S1). 
Parasites, cell culture, infection of mice and treatment schedules. For experimental 
infections, BALB/c mice (6-8 weeks old) were injected intraperitoneally (i.p.) with 10
8
 
stationary phase promastigotes. Infected mice (6 mice/group) received i.v. injection of a 
single-shot treatment of drug-free PLGA-NS (1.5 mg/mouse), AmBisome® (1 mg/kg), and a 
single or three consecutive daily doses of AmB-PLGA-NS (1 mg/kg AmB associated with 
1.5 mg of PLGA-NS) after 14-days of infection. 
In vivo AmB distribution. The analysis of AmB in tissues samples was based on a 
previously described analytical method (23). Homogenized tissues were used for the UPLC 
analysis and the limit of AmB quantification was 20 ng/mL. 
 
T cell proliferation assay. T cell proliferation assay was performed with splenocytes from 
different experimental groups of treated and untreated mice isolated by mechanical disruption. 
After 96 h the proliferation of splenic lymphocytes labeled with carboxyfluorescein succinimidyl 
ester was evaluated by flow cytometry, and T-cell populations identified with APC-conjugated 
anti-mouse CD4 and PB-conjugated anti-mouse CD8. 
 
Analysis of cytokines and total nitrites production. Secreted cytokines were quantified in 
the splenocytes culture supernatants of differently treated infected mice by ELISA as 
recommended by the manufacturer (BioLegend, San Diego CA, USA). The total nitrite oxide 
(NO) content was quantified in supernatants of 72 h-culture of splenocytes recovered from the 
different treatment animal groups stimulated, or not, with soluble Leishmania antigens (SLA) 
using the Griess method (24). 
  
In vitro cell-mediated cytotoxicity assays. The in vitro cytotoxicity assay was accomplished 
using a LIVE/DEAD cell-mediated cytotoxicity kit (Molecular Probes, Invitrogen Life 
Technologies, Alfragide, Portugal) according to the manufacturer’s protocol. 
RESULTS 
Physicochemical characterization of nanospheres: size, zeta potential, morphology, 
drug content, storage stability and in vitro release. AmB was encapsulated into PLGA-
NS by nanoprecipitation,
22
 following an optimization step described in Supplementary 
Material (Table S2). The physicochemical properties of the optimized NS such as particle 
size, polydispersity (PDI), ξ-potential and drug encapsulation efficiency (EE) were studied 
and are summarized in Table 1. 
The nanoformulations displayed mean diameter of 187.3 ±1.3 to 221.5 ± 6.6 nm for empty 
and AmB-PLGA-NS, respectively, with low PDI. Loading of the PLGA-NS with AmB led to a 
statistically significant increase on the size (P < 0.05) without disturbing the PDI or the 
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surface charge as shown by constant ζ-potential values around − 18 mV. TEM photographs 
revealed that empty (Figure 1, A) and AmB-PLGA-NS (Figure 1, B) were found to be 
homogeneous and spherically shaped. Moreover, the AmB-PLGA-NS could be obtained in a 
reproducible and industrial-sized production within a short period of time (6 h). The 
encapsulation efficiency was determined by UPLC analysis of AmB-loaded 
nanoformulations. The AmB loading was calculated to be about 130 μg/mg of PLGA, which 
represented an EE of 65%. 
The influence of pH on the AmB release profile from the PLGA-NS for 10-days is shown on 
Figure 1, C. For both physiologic and acidic pH conditions the NS displayed a biphasic pattern 
characterized by a burst release of AmB that lasted approximately 6 h, followed by a 
continuous release of the drug for at least 10-days. Yet, the effect observed during the first 
phase of release was much more drastic at acidic than at physiologic pH (P < 0.05). 
The AmB-PLGA and unloaded PLGA-NS did not show any signs of aggregation during the 
purification steps and remained stable upon storage at 4 °C for at least 60-days, as no 
significant changes were observed on their particle size, PDI and ζ-potential (Figure 1, D-E). 
With the increase of the storage period the nanoformulations were found slightly less negative 
than the freshly prepared nanoformulations (P < 0.05) (Figure 1, D) with higher tendency to 
aggregate (PDI > 0.1) and a non-significant size increase (Figure 1, E). No modification was 
found on the AmB content when the PLGA-NS were stored at 4 °C up to 60-days (data not 
shown). 
To evaluate the in vitro stability of AmB-PLGA-NS under sub-tropical and tropical 
temperatures, the nanoformulations were incubated at 30 and 42 °C. Regarding the drug 
content, the temperature did not affect the stability of AmB in PLGA-NS, exceeding 
94.38% ± 3.56% (Figure S1D, light grey) and 86.12% ± 4.28% (Figure S1D, dark grey) of its 
initial concentration after 30-days at 30 °C or 42 °C, respectively. Nevertheless, this decrease 
on the AmB content inside the PLGA-NS did not affect its efficacy. Indeed, the anti-
leishmanial activity of AmB-PLGA-NS stored at 30 °C for 60-days exhibited an IC50 value of 
0.16 ± 0.03 μg/mL against intracellular L. infantum amastigotes in THP1 differentiated 
macrophages, which is remarkably similar to the one observed with freshly prepared NS 
(0.13 ± 0.02 μg/mL, p > 0.05). 
In vivo efficacy of the AmB-PLGA nanospheres. AmB-PLGA-NS led to a marked in vitro 
anti-leishmanial outcome (Figure S2, Table S3) hence the efficacy of the AmB-PLGA-NS was 
assessed in a VL susceptible murine model by a single- or a three-daily dose treatment at 
1 mg/kg. In all treated groups a significant reduction (P < 0.001) of the parasite load was 
found on the splenic and hepatic tissues (Figure 2, A and B). When given in a single-dose or 
3-daily doses at 1 mg/kg, AmB-PLGA-NS promoted a reduction of 98.6% ± 1.4% and 
99.3% ± 0.5%, respectively, in the splenic parasites corresponding to approximately 100-fold 
decrease, as compared to the vehicle control. Concerning the liver, a less effective outcome 
was observed, with 90.6% ± 0.7% and 98.7% ± 0.8% parasite reduction for AmB-PLGA-NS 
given in single or 3-daily doses, respectively, related to the vehicle control. Importantly, the 
AmB-PLGA-NS led to a more pronounced reduction on the splenic parasites when compared 
with AmBisome® irrespective of the number of doses given (P < 0.05) (Figure 2, A). In the 
liver, a 3-consecutive daily dose was as effective as AmBisome® in reducing the parasite 
burden (Figure 2, B). 
In vivo AmB distribution. In order to clarify the high splenic efficacy of AmB-PLGA-NS we 
were interested in understanding the distribution pattern of AmB when given as Fungizone® 
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(0.8 mg/kg), AmBisome® (1 mg/kg) and PLGA NS (1 mg/kg) by i.v. to infected animals. 
Fungizone® was chosen for comparison as another amphotericin B formulation clinically 
used. The results of tissue distribution of AmB 2 h following i.v. administration of the three 
formulations are summarized in Table 2. 
Following i.v. administration of PLGA-NS and AmBisome®, AmB accumulates mainly in the 
spleen and liver, in comparison to other tissues (kidney, lung and heart). Furthermore, an 
impressive amount of AmB from the PLGA-NS is focused on the spleen, being approximately 
2-fold less present in the liver. In opposition, AmB delivered by AmBisome® accumulates 
twice more in the liver than in the spleen. Even so, the overall concentrations in these two 
Leishmania-target organs are not significantly different for those two AmB formulations. 
Toxicological studies. The safety of a new VL treatment is as fundamental as its efficacy. By 
assessing the oxidative stress it is possible to ascertain tissue toxicity elicited by the 
administration of the AmB treatments (25). Therefore, we evaluated biomarkers of oxidative 
stress in the liver and spleen, namely reduced (GSH) and oxidized glutathione (GSSG). 
The measurement of the ratio of reduced GSH to GSSG in the liver showed a statistical 
significant decrease (P < 0.01) for PLGA-NS-, single- and 3-consecutive doses-AmB-PLGA-
NS, and AmBisome®-treated groups when compared with the untreated group (Figure 3, A). 
Similarly, in the spleen (Figure 3, B) a statistical decrease (P < 0.05) for PLGA-AmB-treated 
group was observed. The extent of drug-induced tissue toxicity by ROS was further 
determined by means of lipid peroxidation and myeloperoxidase activities in the liver and 
spleen, but no statistically significant differences were observed within all the experimental 
groups in the tissues analyzed (Figure S3). 
AmB-PLGA nanospheres positively interact with the immune system. Further 
experiments were performed to evaluate if AmB-PLGA-NS induce a protective modulation of 
adaptive immunity besides the anti-leishmanial activity in VL mice model. 
Splenocytes from AmB-PLGA-NS treated animals showed enhanced CD4
+
 and CD8
+
-T cell 
proliferation in response to SLA (P < 0.001), while empty NS and AmBisome® treatment had 
little or no effect on lymphocytes proliferation (Figure 4, A). Even though the development of T 
cell specific proliferation was observed with a single-dose of AmB-PLGA-NS, the effect was 
more pronounced with the 3-consecutive daily administrations (Figure 4, A). The development 
of a T-cell specific response did not result from a quantitative modification of the spleen 
cellular populations (Figure S4) or to significant changes on their activation status (Figure S5). 
Instead, we detected a significant increase on the number of effector memory CD8
+
-T cells 
(Figure 4, B), and CD4
+
-T cells to a lower extent (~ 4%, Figure S6), after treatment with AmB-
PLGA-NS. Indeed, the analysis of the CD8
+
-T cell phenotype obtained from AmB-PLGA-NS 
treated mice revealed a predominant effector memory subset (CD44
+
CD62L
low
) as compared 
to CD8
+
-T cells from controls (Figure 4, B). These qualitative changes in the lymphocytes sub-
populations led us to investigate their function in terms of cytokine profile developed during 
AmB-PLGA-NS treatment. We detected a 1.5- (P < 0.05) and 2-fold (P < 0.001) increase in 
the frequencies of IFNγ
+
 CD4
+
-T cells and 2.6 (P < 0.01) and 5.1-fold (P < 0.001) 
enhancement of IFN-γ
+
-CD8
+
 T cells exclusively for the groups that received a single-dose 
and a 3-consecutive daily doses of AmB-PLGA-NS, respectively (Figure 4, C). Although 
AmBisome® has proved to elicit similar reductions on parasite burden, we did not detect any 
significant production of IFN-γ in both splenic CD4
+
 or CD8
+
-T cells. In all the treated groups 
(PLGA, AmB-PLGA-NS and AmBisome®), IL-10
+
 producing CD4
+
 and CD8
+
-T cell 
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populations did not change with respect to untreated controls (Figure S7A, B). Moreover, the 
IFN-γ
+
 producing CD4
+
-T cells developed in AmB-PLGA-NS treated mice failed to produce IL-
10 (data not shown). The cytokine quantification of splenocytes supernatants re-stimulated 
with SLA confirmed these findings. AmB-PLGA-NS treated mice exhibited IL-12 and IFN-γ 
levels significantly higher (P < 0.001) in comparison with untreated, AmBisome® or empty 
PLGA-NS treated infected animals (Figure 4, D). Indeed, IL-12 was ~ 2- and 3-fold higher in 
single and 3-consecutive daily doses, respectively, which may account for the increase of IFN-
γ levels in 8 and 11.5-fold in the animals that received single and 3-doses, respectively, of 
AmB-PLGA-NS. In opposition, IL-10 secretion was found to be restrained in both AmB-PLGA-
NS or AmBisome® treated infected animals (Figure 4, D). This cytokinic microenvironment 
ultimately resulted in an increase of NO production (Figure 4, E). The AmB-PLGA-NS treated 
animals had a 5- and 6-fold increase in nitrite production, for single and 3-consecutive daily 
doses, respectively in comparison with the infected untreated animals, while AmBisome® 
treated animals showed a 2-fold increase when compared with infected untreated animals 
(Figure 4, E). 
Leishmania-specific cell-mediated response by antigen-specific cytotoxic T lymphocytes or 
innate cells is a part of the effective immune response developed against the parasite (26). 
Antigen-specific cytotoxic T lymphocytes or innate cells are responsible for this cytotoxic 
activity. In this study, our results provided evidence that the immune-stimulatory effect of 
AmB-PLGA-NS treatment acts by creating an immunological environment unfavorable for 
parasite survival and growth. Thus, we have investigated if the AmB-PLGA-NS treatment is 
also able to induce a Leishmania-specific cytotoxic response. Splenocytes from all 
experimental treatment groups were stimulated ex vivo with SLA for 7-days, to favor the 
expansion of Leishmania-specific clones. The cytotoxic response of these cells was then 
evaluated against L. infantum-infected macrophages, revealing a dose-dependent lysis of the 
target cells (infected macrophages) (Figure 4, F). Indeed, splenocytes recovered from AmB-
PLGA-NS treated mice were able to elicit a statistically significant (P < 0.001) dose dependent 
lysis of the target cells of 31.5% and 28.2% for a 3-consecutive daily doses and a single-dose, 
respectively, at 40:1 (effector: target) ratio. In opposition, empty PLGA-NS or AmBisome® 
treated infected mice showed no specific cytolysis (Figure 4, F). These results demonstrate 
that AmB-PLGA-NS induced the generation of Leishmania-specific effector cytotoxic T cells 
that act synergistically with the anti-leishmanial activity of AmB in the elimination of infected 
macrophages. Importantly, this AmB-PLGA-NS formulation induced a strong adaptive immune 
response in addition to the anti-parasitic effect, which is absent upon treatment with the 
AmBisome® formulation. 
Efficacy of AmB-PLGA nanospheres is associated with CD8
+
 T cells. Our results 
demonstrate that the AmB-PLGA-NS amplified the cellular response to Leishmania infection 
manifested by the development of antigen-specific T lymphocytes with the concomitant 
secretion of IFN-γ. Previous studies have demonstrated that CD4
+
 and CD8
+
-T cells play a 
crucial role in the control of Leishmania infection characterized by IFN-γ secretion (27, 28). To 
ascertain the relevant cellular mechanisms responsible for the improved protection induced by 
the AmB-PLGA-NS, we separately assessed the contributive role of each player (IFN-γ and 
CD4
+
-, CD8
+
-T cells). Surprisingly, AmB-PLGA-NS was as effective in reducing the parasite 
load in spleen and liver of IFN-γ−/− mice as the wild type control (Figure S8). Since our results 
demonstrate a Leishmania-specific T cell response upon AmB-PLGA-NS treatment (Figure 4, 
F), we investigated separately the potential role of CD4
+
- and CD8
+
-T cells. To do so, we have 
depleted each population before AmB-PLGA-NS treatment by injecting L. infantum infected 
BALB/c mice with anti-CD8 or anti-CD4 monoclonal antibody (Figure S9). Remarkably, the 
treatment with AmB-PLGA-NS failed to control the infection in CD8
+
 depleted mice (Figure 5, 
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A). Mice depleted of CD4
+
 cells but maintaining functional CD8
+
-T cells were fully capable to 
elicit a reduction on the parasite burden after AmB-PLGA-NS treatment (Figure 5, A). In 
addition, the depletion of CD8
+
-T cells abrogated the cytotoxic activity of AmB-PLGA-NS-
pulsed splenocytes against infected host macrophage cells (Figure 5, B) while the depletion of 
CD4
+
-T cells had little effect. Finally, only CD8
+
-T cells purified from the spleen of AmB-PLGA-
NS treated infected mice exhibited similarly a cytotoxic activity upon infected host 
macrophages (Figure 5, C).These data demonstrate the crucial role for Leishmania-specific 
cytotoxic CD8
+
-T effector cells in the killing of L. infantum-infected macrophages in mice that 
have previously received AmB-PLGA-NS. 
RESULTS 
A low cost polymeric system for AmB using PLGA nanospheres was described. Our approach 
produced a tropically stable and safe DDS with an insight on the splenic cellular immune 
mechanisms responsible for the efficient response after VL treatment. 
When defining a DDS for AmB it is important to consider the hydrophobicity of the compound 
and the importance of its controlled and sustained release into the surrounding environment. 
Biodegradable nanoparticles can be produced from natural or synthetic polymers, the latter 
being advantageous for prolonged release of the encapsulated therapeutic agents that can 
span for some days to several weeks (29). The polylactides and PLGA are among the most 
extensively investigated for drug delivery (30). As polyesters in nature, these polymers 
undergo hydrolysis in the body, forming moieties that are eventually removed from the body 
by the citric acid cycle. Introduced by Fessi (22) nanoprecipitation is a simple and mild method 
for the preparation of nanoparticles without the use of any preliminary emulsification. This 
method presents several advantages, since it does not involve aggressive steps (such as 
sonication, high temperatures and extended stirring rates), surfactants are not always needed 
and the organic solvents normally used do not display significant toxicity and, it is highly 
recommended for hydrophobic drugs (31, 32) Taking all these into consideration, the 
development of the AmB DDS was primarily based on the PLGA polymer and the 
nanoprecipitation method. Starting with a small AmB amount the drug was successfully 
loaded on PLGA-NS with a 65% EE value, which can be related to the nanospheres 
preparation method but also to the possible electrostatic interaction between capped carboxyl 
groups of PLGA and the positively charged primary amine group of AmB contributing to such 
a drug entrapment. Comparable drug EE values above 50% for AmB in PLGA nanoparticles 
are described in literature with higher initial drug loading values (10% to 30%) (15, 16). The 
AmB entrapment on the PLGA-NS leads to a statistically significant increase of about 30-nm 
on the nanospheres size (P < 0.05) without affecting the morphology, PDI and ζ-potential. It is 
well established that the stabilizer PVA forms a layer protecting the nanospheres from 
aggregation and that its residual amount remaining onto the nanospheres is relatively high 
due to strong attachment to the surface (33).  
Assessment of the AmB in vitro release revealed pH dependence and since in VL the 
pathogen resides inside an acidic phagolysosome of macrophages, the AmB in vitro release 
profile suggests retention of the drug inside the NS on the mammalian cell cytoplasm and 
preferential release at the endosomal–lysosomal acidic pH. Indeed, after 6 h at pH 5.5, 
49.99% ± 2.92% was found to be released from the NS whereas only 18.56% ± 2.16% of AmB 
was released from the PLGA-NS under pH 7.4. Afterwards, a similar tendency of slower drug 
release was maintained for the period of 10-days, revealing 88.40% ± 3.56% and 
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60.23% ±2.03% AmB released from the PLGA-NS under acidic pH and physiological 
conditions, respectively. 
Based on the accelerated temperature studies set out by the WHO to mimic tropical climate 
Zone 3 and 4 conditions (34), we analyzed the storage stability of the developed AmB-PLGA-
NS at 30  °C and 42 °C in defined time points over a 60-day period. Our nanoformulations 
improved AmB stability when compared with four AmB lipid formulations recently presented 
with remarkable temperature stability with about 80% after 30 to 60 days at 30 °C and 75% at 
43 °C in drug content (34). Besides, AmB-PLGA-NS stored for 60-days at 30 °C behave 
similarly to fresh preparations as observed by the determination of the in vitro activity on L. 
infantum intracellular amastigotes. All these data allow us to affirm that the AmB-PLGA-NS 
are a sub-tropically stable formulation. 
The effectiveness of the AmB-PLGA-NS was assessed in a VL susceptible murine model. The 
single-dose i.v. administration of AmBisome® resulted in 95.9% ± 1.1% to 99.0% ± 0.5% 
inhibition of spleen and liver parasites, respectively, consistent with literature reports (35, 36). 
When given in a single dose or 3-daily doses AmB-PLGA-NS led to a statistically significant 
reduction of splenic and liver parasites, corresponding to approximately 2-log10 decrease, as 
compared to the vehicle control. Our data clearly demonstrate the advantageous efficacy of a 
single-dose of the AmB-PLGA-NS in reducing splenic parasites when compared to 
AmBisome® (P < 0.05). This new DDS intravenously administered can be a promising 
approach for a structured VL treatment, preventing uncontrolled drug self-administration (e.g. 
oral route) as well as the emergence of AmB resistant strains. 
In view of our in vivo results on VL murine model, we were interested in understanding the 
bio-distribution pattern of AmB when given as Fungizone®, AmBisome® and PLGA-NS by i.v. 
to infected animals. Both PLGA-NS (~ 200 nm) and AmBisome® (~ 100 nm) are particulate 
systems recognized by the mononuclear phagocyte system (MPS) (primarily liver, spleen and, 
to a lesser extent, lungs), while Fungizone®, a colloidal micellar system with about 1 μm size, 
is able to avoid the effect of the MPS (37). In fact, Fungizone® displayed a more homogenous 
distribution on the tissues, with an evident retention in the kidney, which may be correlated 
with its well-known nephrotoxicity (38, 39). Interestingly, the concentration of AmB in tissues 
2 h following i.v. administration of PLGA-NS and AmBisome® reveals some similarities. In 
both cases, most of the drug is found in major MPS-riched tissues, liver and spleen. Given the 
bio-distribution of PLGA-NS and AmBisome® among the splenic and hepatic tissues, these 
findings support the higher effectiveness of PLGA-NS observed in the splenic parasites 
reduction in the VL murine model. 
The safety of the VL treatment is as fundamental as its effectiveness. By assessing the 
oxidative stress, a marker of drug-induced organ toxicity (40), it is possible to ascertain tissue 
toxicity elicited by the administration of the AmB treatments (25). Here we have evaluated the 
effects of all the VL treatments on the liver and spleen by quantifying several oxidative stress 
indicators. Given that the developed AmB-PLGA-NS exhibited similar oxidative stress levels 
when compared to AmBisome® and the untreated group it can be considered that identical 
drug-induced toxicity levels were caused in the liver or spleen. Nevertheless, extensive in vivo 
studies consisting of the assessment of nephrotoxicity and hepatotoxicity respectively of the 
new AmB-PLGA-NS will be addressed in the near future. 
The profound impairment of the immune system of the infected host in VL is a major cause for 
incomplete efficacy of the anti-leishmanial chemotherapy, as the treatment success depends 
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on the combined effect of the drug itself and the immune status of the host (41, 42). Our 
results suggest that AmB-PLGA-NS improve the inherent immune-modulatory efficacy of 
AmB, most probably by directing towards a Th1 immune response, which is essential for a 
successful VL treatment. Th1 cells secreting large amounts of IFN-γ will enhance cellular 
immunity by cytotoxic T lymphocytes and macrophages (43). It has been described the 
requirement of continuous presence of IL-12 for sustaining Th1 immunity, providing protective 
cell-mediated immune response towards murine L. major infection (44). Indeed, our data show 
a substantial reduction in splenic parasite burden and high levels of IL-12 and IFN-γ, which 
verify these findings. Similarly, a high level of NO production in the AmB-PLGA-NS treated 
mice suggests the induction of NO-mediated macrophage effector mechanisms towards the 
control of parasite proliferation (45, 46). Moreover, IL-10 is considered to be the predominant 
immunosuppressive cytokine leading to susceptibility (47, 48). We detect a downregulation of 
IL-10 production either by lymphocytes or from other cellular origin. In this study, our results 
emphasize the importance of effective immune stimulation combined with anti-leishmanial 
activity for VL treatment. In the same way, it was described by others that AmB entrapped in 
stearylamine cationic liposomes was more effective in killing L. donovani and in retaining the 
immunomodulatory effect of free AmB on CD4
+
 and CD8
+
-T cells for IFN-γ production than 
AmBisome® (48). The AmB-PLGA-NS was able to preserve and develop the 
immunomodulatory effect already described for AmB (49), while AmBisome® did not, possibly 
due to different uptake mechanism and intracellular tracking of these two DDSs which may 
lead to different outcomes in the macrophage modulation and consequently T cells function. 
As a final point the efficacy of AmB-PLGA-NS was correlated to the CD8
+
-T cells function. 
Currently, it is known that CD8
+
-T cells play an important role in the mechanisms for the cure 
and the resistance to Leishmania infection, either by the production of IFN-γ and activation of 
macrophages, or by the direct killing of parasitized macrophages, or a combination of both 
effects (27, 28, 49). Therefore, targeting CD8
+
-T cells responses may have great therapeutic 
potential against VL. 
Here we have demonstrated that the incorporation of AmB in PLGA-NS is able to reduce 
experimental VL when CD8
+
-T cells are present. Although nanoparticles are considered an 
efficient tool for inducing potent immune responses and several vaccine applications have 
been described (50), to the best of our knowledge, we describe here for the first time the 
crucial role of CD8
+
-T cells in the in vivo efficacy of a nano-therapy approach against 
intracellular Leishmania protozoan. Based on the present results, the developed AmB-PLGA-
NS can be a promising approach for VL treatment, especially in tropical and subtropical 
developing countries where an affordable and effective approach is urgently needed. 
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Figure 1. Characterization of the AmB-PLGA nanospheres. Morphology of unloaded (A) and AmB-loaded (B) PLGA-
NS; scale bar is 500 nm. (C) AmB in vitro release kinetics from PLGA-NS at pH 5.5 (●) and pH 7.4 (◊); means ± SDs 
(n = 5). (D) Storage stability for unloaded (white bars; squares) and AmB-loaded (dark bars; triangles) PLGA-NS at 
4 °C for 2-months according to size (bars) and PDI (lines) and (E) ζ-potential. 
 
 
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
  
Figure 2. In vivo efficacy of AmB-PLGA nanospheres in L. infantum-infected mice. 3-days after the last 
administration, parasite burden was evaluated by limiting dilution assay in the spleen (A) and in the liver (B). Data 
represent the mean ± SD of a representative experiment from two carried out independently, with six mice per 
experimental group in each experiment *P < 0.05, **P < 0.01 and ***P < 0.001 in comparison with untreated group. 
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Figure 3. Measurement of the ratio of reduced glutathione to oxidized glutathione. (A) Liver and (B) spleen of 
Leishmania-infected mice untreated or treated. Values are given as mean ± SEM (n = 4). The comparison between 
untreated infected group and the different treatment groups was made with the one-way analysis of variance 
(ANOVA) with Dunnett’s multiple comparison test. 
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Figure 4. In vivo mechanism of AmB-PLGA nanospheres in L. infantum-infected mice. (A)In vitro proliferation of 
splenic cells of differently treated mice. (B) Phenotype of CD8
+
 memory T cells. (C) Intracellular and secreted IFN-γ, 
IL-12p40 and IL-10 production of total CD4
+
- and CD8
+
-T cells from all experimental groups. (E) NO production. (F) 
AmB-PLGA-NS treatment causes a Leishmania-specific cytotoxic response. Data represent the mean ± SD of a 
representative experiment from two carried out independently, with six mice per experimental group in each 
experiment *P < 0.05, **P < 0.01 and ***P < 0.001 in comparison with untreated group. 
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Figure 5. CD8
+
-T cells are crucial for the in vivo efficacy of AmB-PLGA nanospheres in L. infantum-infected mice. 
(A) Parasite load in PBS, PLGA-NS or AmB-PLGA-NS treated mice depleted of CD4
+
 and CD8
+
-T cells prior 
treatment. Untreated and (PBS) treated mice with IgG were used as controls. (B, C) AmB-PLGA-NS treatment 
causes a Leishmania-specific cytotoxic response dependent on CD8
+
-T cells. Data represent the mean ± SD of a 
representative experiment from two carried out independently, with four mice per experimental group in each 
experiment *P < 0.05, **P < 0.01 and ***P < 0.001 in comparison with untreated group. 
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GRAPHICAL ABSTRACT 
 
 
 
 
 
 
 
Proposed mechanism of action of AmB-PLGA nanospheres on Leishmania-infected macrophages and 
interaction with CD8
+
 T cells. 
